Five Years Later, the First Pot Stock Is Up 2,139% Since Its Debut
(Bloomberg) -- Five years ago today, the first pot stock began trading on the public markets, prompting a few raised eyebrows and many, many bad puns. Today, that company is worth nearly $15 billion.
Canopy Growth Corp., then known as Tweed Inc., listed on Toronto's TSX Venture Exchange on April 4, 2014 via a reverse takeover of a capital pool company. Shares closed that first day at C$2.59 and have gained over 2,139 percent since then to C$58 Thursday morning. If you were lucky enough to sell at its high of C$76.91 in October, your return would have been 2,869 percent.
At the time of the stock's debut, Canada had only recently licensed the first commercial growers to provide marijuana to the country's expanding base of medical users. The Conservative federal government under then-Prime Minister Stephen Harper had no intention of legalizing recreational use and it was unclear what the sector would look like in one year, much less five.
But Canopy, under chief executive officer Bruce Linton, bet that investors would want a piece of the cannabis industry. Since then, it's been a consistent trailblazer on the public markets. It was the first marijuana company to uplist to the Toronto Stock Exchange, the first to be added to Canada's benchmark S&P/TSX Composite Index, the first to hit $1 billion in market value and the first to list its shares on the New York Stock Exchange.
It was also the first pot company to secure a major investment from a partner outside the industry when it announced an initial C$245 million investment from Constellation Brands Inc. in October 2017 followed by an additional C$5 billion in August 2018.
Linton himself has been a beneficiary of the gains. His stake of 2.5 million shares is worth C$145 million on paper, according to Bloomberg data.
Other pot companies that went public in 2014 have also thrived.
Cronos Group Inc., which recently closed a C$2.4 billion investment from tobacco firm Altria Group Inc., has gained nearly 3,000 percent from its first trading day on Dec. 17, 2014 when it was known as PharmaCan Capital Corp. Aphria Inc. is up nearly 1,500 percent since its debut on Dec. 8, 2014 and Organigram Holdings Inc. has gained about 400 percent from its closing price of C$1.97 on its first trading day of Aug. 25, 2014.
To contact the reporter on this story: Kristine Owram in Toronto at kowram@bloomberg.net
To contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Will Daley
©2019 Bloomberg L.P.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.